INNOVADERM CRO IS NOW INDERO.

Conducting a Successful Medical Aesthetic Trial—Expert Strategies

Indero

Indero

Team of Experts

Author picture

aesthetic dermatology

Table of contents
Key components to maximize a trial’s success
1. Site Selection and Patient Engagement
2. Open Communication With Key Stakeholders
3. Prioritization of the Quality of Collected Data and Outcomes 
4. Novel Treatments Generate Interest

 

The medical aesthetic market presents itself as a dynamic frontier with immense possibilities. Site selection, patient enrollment optimization, proper collection of relevant data, and proper operationalization set up, all have a direct influence on the progress of a medical aesthetic trial. Thus, closely exploring these key components will maximize a trial’s success.  

Site Selection and Patient Engagement 

Site Selection and Patient Engagement

The site selections should be made in accordance with the following criteria:  

  • the availability and competency of clinical personnel 
  • potential burden on the sites 
  • patients user-friendly research equipment 
  • any country specific government regulations that might affect the trial. 

 

Unlike dermatology patients, who generally seek treatment, the patients involved in medical aesthetics trials are usually in good health and looking for an aesthetic improvement. The study conduct should allow for as much flexibility as possible to accommodate participants’ work schedules and contribute to patient enrollment and continued engagement until study is completed. Close enrollment tracking and ensuring the sites’ capacity to handle large patient flow is also imperative to medial aesthetic trials that tend to attract a lot of interested patients. 

Open Communication With Key Stakeholders 

Open Communication With Key Stakeholders

Effective communication between the sites, participants, CRO and sponsor is of paramount importance throughout all stages in trial execution. Well-established communication channels can fortify key partnerships. One of them is partnering with research sites that will maximize site engagement and contributions. This dialogue must start from the onset of site selection through to the completion of the study. The CRO should strive to keep the sites engaged and informed about study progress, important timelines and milestones expected to be met. 

Prioritization of the Quality of Collected Data and Outcomes 

The collection of data in a clinical trial is critical for providing valuable insight into the safety and efficacy of experimental therapies. To the same degree, special attention should be paid to the optimization of the technology used for the collection of this data, such as photography equipmentPatient-Reported Outcomes (PROs) devices, electronic data capture platforms, etc. These processes reduce complexity, lighten the site staff workload, and minimize time spent troubleshooting. Additionally, patients should be provided with instructions, from the site staff on completion of PROs. To ensure the accuracy of the patient’s responses, it is necessary that patient feedback is obtained before any other on-site procedure. Any distractions or conversations must be prevented to secure the highest quality of PRO data.

Novel Treatments Generate Interest 

Novel Treatments Generate Interest 

Site investigators may show greater enthusiasm when approached for a medical aesthetic trial in general, and especially when such trials are evaluating a novel product or novel mechanism of action. This level of enthusiasm often translates to larger volume of patients being enrolled in the trial.  

Medical aesthetic trials are intricate and require extensive preparation in their execution. It is essential to select the best-suited sites and to implement a protocol designed to provide significant scientific and medical value while enabling patient recruitment and minimizing the burden on site staff. Thoughtful planning and collaboration from all parties are key contributors to the success of a medical aesthetic clinical trial.  

At Indero, we believe that medical aesthetic trials should be conducted with the utmost care. Our team of experts specializes in the design, organization, and implementation of studies and ensures that every detail is meticulously considered. Contact us to learn more about how we can help you achieve your clinical trials ambitions.  

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.